Evolving management of pediatric pulmonary arterial hypertension: Impact of phosphodiesterase inhibitors

Pediatric Cardiology

Volumn 34, Issue 2, 2013, Pages 213-219

  Wardle, Andrew James ^a   Tulloh, Robert M R ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Hypertension pulmonary; Pediatrics; Phosphodiesterase inhibitors; Sildenafil

Indexed keywords

BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; MILRINONE; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTANOID; SILDENAFIL; TADALAFIL; VARDENAFIL;

ABDOMINAL DISCOMFORT; CLINICAL FEATURE; DISEASE CLASSIFICATION; DIZZINESS; DOWN SYNDROME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; EXTRACORPOREAL OXYGENATION; FLUSHING; HEADACHE; HUMAN; JAW PAIN; LIVER TOXICITY; LUNG TRANSPLANTATION; MEAN ARTERIAL PRESSURE; METHEMOGLOBINEMIA; MONOTHERAPY; NAUSEA; OPTIMAL DRUG DOSE; PREVALENCE; PROGNOSIS; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SEX DIFFERENCE; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

CHILD; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE INHIBITORS; PULMONARY WEDGE PRESSURE; TREATMENT OUTCOME;

EID: 84879498260     PISSN: 01720643     EISSN: 14321971     Source Type: Journal    
DOI: 10.1007/s00246-012-0598-8     Document Type: Review

References (30)

1. Atz AM, Lefler AK, Fairbrother DL et al (2002) Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises. J Thorac Cardiovasc Surg 124:628-629
2. Badesch DB, Champion HC, Sanchez MA et al (2009) Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54(Suppl 1):S55-S66
3. Barst RJ, Oudiz RJ, Beardsworth A et al (2011) Pulmonary arterial hypertension and response to tadalafil (PHIRST) study group: tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant 30:632-643
4. Barst RJ, Dunbar I, Gaitan G et al (2012) A randomised double-blind placebo-controlled dose-ranging study of oral sildenfail citrate in treatment naive children with pulmonary arterial hypertension. Circulation 125:324-334
5. Barst RJ, McGoon MD, Elliott CG et al (2012) Childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation 125:113-122
6. Bassler D, Choong K, McNamara P et al (2006) Neonatal persistent pulmonary hypertension treated with milrinone: four case reports. Biol Neonate 89:1-5
7. Berger RM, Beghetti M, Humpl T et al (2012) Clinical features of paediatric pulmonary hypertension: a registry study. Lancet 379:537-546
8. Carroll WD, Dhillon R (2003) Sildenafil as a treatment for pulmonary hypertension. Arch Dis Child 88:827-828
9. Della Torre F, Della Torre E, Di Berardino F (2005) Sildenafil in pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 22:78-79
10. Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF family signalling. Nature 425:577-584
11. Fraisse A, Jais X, Schleich JM et al (2010) Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France. Arch Cardiovasc Dis 103:66-74
12. Galie JN, Brundage BH, Ghofrani H et al (2009) Tadalafil therapy for pulmonary arterial hypertension. Pulmonary arterial hypertension and response to tadalafil (PHIRST) study group. Circulation 119:2894-2903
13. Hawkins A, Langton-Hewer S, Henderson J et al (2011) Management of pulmonary hypertension in down syndrome. Eur J Pediatr 170:915-921
14. Humpl T, Reyes JT, Holtby H et al (2005) Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single drug, open-label, pilot study. Circulation 111:3274-3280
15. Jing ZC, Yu ZX, Shen JY et al (2011) Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Efficacy and safety of vardenafil in the treatment of pulmonary arterial hypertension (evaluation) study group. Am J Respir Crit Care Med 183:1723-1729
16. Karasu-Minareci E, Ozbudak I, Ozbillim G, et al (2012) Acute effects of vardenafil on pulmonary artery responsiveness in pulmonary hypertension. Sci World J 2012. doi: 10.1100/2012/718279
17. Karatza AA, Bush A, Magee AG (2005) Safety with pulmonary hypertension. Int J Cardiol 100:267-273
18. Lowe G, Costabile R (2012) 10-year analysis of adverse event reports to the food and drug administration for phosphodiesterase type-5 inhibitors. J Sex Med 9:265-270
19. Moledina S, Hislop AA, Foster H et al (2010) Childhood idiopathic pulmonary arterial hypertension: a national cohort study. Heart 96:1401-1406
20. Namachivayam P, Theilen U, Butt WW et al (2006) Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med 174:1042-1047
21. Simmoneau G, Robbins IM, Beghetti M et al (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54:S43-S54
22. Simonneau G, Rubin LJ, Galie N et al (2008) Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 149:521-530
23. Spring RM, Ulrich S, Huber LC et al (2008) Sildenafil for pulmonary hypertension: dose-dependent improvement in exercise performance. Pulm Pharmacol Ther 21:516-521
24. Sun X, Li Z, Liu Y et al (2010) Inhibition of cGMP phosphodiesterase 5 suppresses matrix metalloproteinase-2 production in pulmonary artery smooth muscle cells. Clin Exp Pharmacol Physiol 37:362-367
25. Takatsuki S, Calderbank M, Ivy DD (2012) Initial experience with tadalfil in pediatric pulmonary arterial hypertension. Pediatr Cardiol 33:683-688
26. Torres F, Gupta H, Soto F, et al (2011) Safety and efficacy of bosentan in combination with sildenafil in pulmonary arterial hypertension: the COMPASS-3 Study (abstract). In: ERS Annual Congress 2011
27. Tudor A, Muşat A, Bari M et al (2005) Observations on peripheral microcirculation in young hypertensive patients. Rom J Intern Med 43:73-78
28. U.S Food and Drug Administration (2012) FDA drug safety communication: FDA recommends against use of Revatio in children with pulmonary hypertension. http://www.fda.gov/Drugs/DrugSafety/ucm317123.htm. Accessed 11 Mar 2012
29. Wirostko B, Trssler C, Hwang L et al (2012) Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double-masked, placebo-controlled trial and open label extension. BMJ 344:e554
30. Wrishko RE, Dingemanse J, Yu A et al (2008) Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J Clin Pharmacol 48:610-618